Insider Selling: G1 Therapeutics Inc (GTHX) Director Sells $497,200.00 in Stock

G1 Therapeutics Inc (NASDAQ:GTHX) Director Seth Rudnick sold 10,000 shares of the business’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $49.72, for a total transaction of $497,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seth Rudnick also recently made the following trade(s):

  • On Tuesday, September 4th, Seth Rudnick sold 10,000 shares of G1 Therapeutics stock. The shares were sold at an average price of $59.95, for a total transaction of $599,500.00.
  • On Monday, August 6th, Seth Rudnick sold 10,000 shares of G1 Therapeutics stock. The shares were sold at an average price of $50.69, for a total transaction of $506,900.00.

GTHX stock opened at $44.69 on Monday. The stock has a market capitalization of $1.75 billion, a P/E ratio of -12.52 and a beta of -1.02. G1 Therapeutics Inc has a 52 week low of $18.03 and a 52 week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.64) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.01. Equities analysts expect that G1 Therapeutics Inc will post -2.68 EPS for the current year.

A number of brokerages have recently issued reports on GTHX. HC Wainwright reissued a “buy” rating and issued a $79.00 target price on shares of G1 Therapeutics in a research report on Monday, September 17th. Needham & Company LLC boosted their target price on shares of G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research report on Tuesday, September 18th. BidaskClub cut shares of G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 19th. BTIG Research began coverage on shares of G1 Therapeutics in a research report on Monday, September 10th. They issued a “buy” rating and a $80.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. G1 Therapeutics has a consensus rating of “Buy” and a consensus target price of $74.50.

A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its stake in G1 Therapeutics by 1.2% in the second quarter. FMR LLC now owns 4,902,732 shares of the company’s stock valued at $213,073,000 after purchasing an additional 57,156 shares in the last quarter. BlackRock Inc. raised its stake in G1 Therapeutics by 32.0% in the second quarter. BlackRock Inc. now owns 1,690,360 shares of the company’s stock valued at $73,462,000 after purchasing an additional 409,300 shares in the last quarter. Bank of New York Mellon Corp raised its stake in G1 Therapeutics by 1,497.7% in the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after purchasing an additional 1,183,940 shares in the last quarter. Voya Investment Management LLC raised its stake in G1 Therapeutics by 7,889.9% in the second quarter. Voya Investment Management LLC now owns 449,834 shares of the company’s stock valued at $19,550,000 after purchasing an additional 444,204 shares in the last quarter. Finally, BB Biotech AG acquired a new position in G1 Therapeutics in the second quarter valued at about $15,324,000. 69.17% of the stock is owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

See Also: Return on Investment (ROI)

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply